Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

Nivolumab Alone, Plus Ipilimumab Being Tested in Early-Stage, High-Risk RCC

April 21st 2021

The safety and efficacy of nivolumab, both as a single agent and in combination with ipilimumab, is under investigation in patients with early-stage, high-risk renal cell carcinoma following radical or partial nephrectomy in the phase 3 CheckMate-914 trial.

CCC19 Updates Uncover High All-Cause Mortality in Patients With COVID-19 and Cancer Receiving Select Chemotherapies

April 21st 2021

Patients with cancer who have contracted COVID-19 trend towards having high disease severity and mortality, especially among those with select demographic and clinical characteristics, with certain chemotherapy regimens contributing towards a high all-cause mortality.

Derazantinib Yields 79% DCR in FGFR2+ Advanced Intrahepatic Cholangiocarcinoma

April 21st 2021

Derazantinib demonstrated promising disease control when given to patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusion.

Osimertinib Combos Are Under Evaluation in EGFR+ NSCLC

April 19th 2021

Jyoti D. Patel, MD, discusses the evolving use of osimertinib in EGFR-mutant NSCLC and emerging targeted agents for patients with EGFR exon 20 insertion mutations.

TKIs, New Targets Serve as Active Areas of Exploration in Pancreatic and Extrapancreatic NETs

April 16th 2021

Yoomi Lee, MD, discusses the safety profile of surufatinib and highlighted future directions for patients with pancreatic and extrapancreatic NETs.

Unique Landscape of Actionable Pathogenic Variants Unfolds in Breast and Ovarian Cancers in the Caribbean

April 16th 2021

Sophia George, PhD, and Judith E. Hurley, MD, discuss the importance of the genetic association study, challenges faced with launching such an effort, the key findings from the research, and the clinical implications of the data in the Caribbean as well as the United States

Addition of SDX-7320 to Palbociclib Inhibits Tumor Growth in Breast Cancer Xenografts

April 15th 2021

The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.

Pal Previews Potential Second-line and Beyond Options in RCC

April 15th 2021

Sumanta K. Pal, MD, details ongoing research efforts dedicated to providing additional therapeutic options for patients with RCC in the second-line setting and beyond.

cfDNA, Genetic Assays Inform Important Treatment Decisions in Breast Cancer

April 14th 2021

Genetic assays such as those utilized in the phase 3 TAILORx, MINDACT, and RxPONDER trials are helping to provide valuable insight to inform treatment decisions in patients with breast cancer.

cfDNA Sequencing Shows Utility in Selecting KRAS G12C+ NSCLC for Sotorasib

April 14th 2021

Plasma-based cell-free DNA appears to be a viable strategy comparable with tissue-based testing for selecting patients with KRAS G12C–mutant non–small cell lung cancer for treatment with sotorasib.

Trastuzumab Deruxtecan Benefit/Risk Profile in Advanced Cancer Supported by Pooled Analysis

April 13th 2021

The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.

Tailoring Targeted Therapies in Metastatic CRC

April 13th 2021

Syed Kazmi, MD, highlights the go-to regimens for patients with mCRC.

Adjuvant Nivolumab/Ipilimumab Falls Short of RFS End Point in Resected, Late-Stage Melanoma

April 10th 2021

The addition of ipilimumab to nivolumab as an adjuvant treatment failed to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma.

Abu-Zeinah Shares Next Steps for Research With Interferon-Alpha in Polycythemia Vera

April 9th 2021

Now that interferon-alpha has been shown to prolong survival in patients with polycythemia vera, it is important that investigative efforts focus on developing a better understanding on the biology of the disease and the mechanisms by which the agent actually improves outcomes.

Matsen Spotlights Best Practices for Breast Cancer Surgery Amidst the COVID-19 Crisis

April 7th 2021

The coronavirus disease 2019 pandemic had a tremendous impact on the surgical care of patients with breast cancer; practice patterns needed to be rapidly adjusted to continue to safely provide care during a time when resources were very limited.

Searching for Molecular Targets in Myeloid Malignancies and Beyond

April 6th 2021

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

Utility of HRD Testing in Ovarian Cancer Expands, but Standardization Remains Elusive

April 6th 2021

Thomas C. Krivak, MD, discusses the significance of HRD in ovarian cancer, approved and prospective HRD tests, and considerations for genomic testing in this population.

D-VCd Rises as the New Standard of Care in Newly Diagnosed AL Amyloidosis

April 6th 2021

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.

Immunotherapy Agents Demonstrate Groundbreaking Data in GI Cancers

April 5th 2021

Lakshmi Rajdev, MD, discusses some of the key developments made with immunotherapy in GI cancers and the groundbreaking data that have recently read out to support their use.

Abu-Zeinah Outlines Why Interferon-Alpha Should Be Offered to Both Low- and High-Risk Polycythemia Vera

April 5th 2021

Ghaith Abu-Zeinah, MD, shares what inspired the study examining IFN vs standard strategies, key findings from the research, and the clinical implications of these data on the PV treatment paradigm.